Monte Rosa Therapeutics, Inc. (GLUE) Institutional Ownership

Ownership Summary

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has 156 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 72.6% of Monte Rosa Therapeutics's outstanding shares in December 2025, down from 73.3% in September 2025.
• They increased total shares held in Monte Rosa Therapeutics by 10.73% from last quarter, and the number of investors in GLUE increased 50.0% annually.
• Of these 156 holders, 98 added to their stakes in Monte Rosa Therapeutics, 40 trimmed positions, and 18 made no changes.
• The aggregate institutional position in Monte Rosa Therapeutics amounted to 59.82Mn shares as of December 2025, up by 5.8Mn shares quarter on quarter, and down 3.35Mn shares year over year.
• As of December 31, 2025, NEA Management Company, LLC held the largest stake in Monte Rosa Therapeutics with 7.69Mn shares, accounting for 9.34% of total shares outstanding.
• The biggest buyers of Monte Rosa Therapeutics for the quarter ending December 2025 included TCG Crossover Management, LLC (4.62Mn), State Street Corp (1.26Mn), MPM BioImpact LLC (1.17Mn), BRAIDWELL LP (948.32K), AMERICAN CENTURY COMPANIES INC (736.22K).
• The biggest sellers of Monte Rosa Therapeutics for the quarter ending December 2025 included BVF INC/IL (1.82Mn), FMR LLC (1.51Mn), Versant Venture Management, LLC (1.27Mn), Alphabet Inc. (719.07K), BAKER BROS. ADVISORS LP (570.36K).
• Business Quant data shows the 10 biggest positions in Monte Rosa Therapeutics as of December 2025 are held by NEA Management Company, LLC (7.69Mn), TCG Crossover Management, LLC (4.62Mn), Versant Venture Management, LLC (4.38Mn), BAKER BROS. ADVISORS LP (4.35Mn), BlackRock, Inc. (4.18Mn), BVF INC/IL (3.84Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (3.36Mn), VANGUARD GROUP INC (3.25Mn), State Street Corp (2.11Mn), Aisling Capital Management LP (1.47Mn).